Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ariad Pharmaceuticals, a drug discovery and development company, has announced that US District Court of Delaware granted Amgen's motion for summary judgment of non-infringement of seven claims of US patent based on activities related to Enbrel.
Subscribe to our email newsletter
The court found that administration of Enbrel falls outside the scope of the asserted claims based on the court’s interpretation of these claims to exclude extracellular methods of reducing NF-eB activity.
Harvey Berger, chairman and CEO of Ariad, said: “We are disappointed by these rulings on claim construction and non-infringment, and plan to pursue the appropriate legal action to obtain review of the rulings.”